Department of Human Genetics, McGill University, Montreal, Canada.
Victor Phillip Dahdaleh Institute of Genomic Medicine at McGill University, Montreal, Canada.
JCO Precis Oncol. 2024 Jul;8:e2400094. doi: 10.1200/PO.24.00094.
Genetic susceptibility to nonsyndromic renal cell carcinoma (RCC) remains poorly understood, especially for different histological subtypes, as does variations in genetic predisposition in different populations. The objectives of this study were to identify risk genes for RCC in the Canadian population, investigate their clinical significance, and evaluate variations in germline pathogenic variants (PVs) among patients with RCC across the globe.
We conducted targeted sequencing of 19 RCC-related and 27 cancer predisposition genes for 960 patients with RCC from Canada and identified genes enriched in rare germline PVs in RCC compared with cancer-free controls. We combined our results with those reported for patients from Japan, the United Kingdom, and the United States to investigate PV variations in different populations. Furthermore, we evaluated the performance of referral criteria for genetic screening for including patients with rare PVs.
We identified 39 germline PVs in 56 patients (5.8%) from the Canadian cohort. Compared with cancer-free controls, PVs in (odds ratio [OR], 4.8 [95% CI, 2.7 to 7.9], = 3.94 × 10) and (OR, 4.5 [95% CI, 2.0 to 8.7], = .016) were significantly enriched in patients with clear cell, whereas PVs in (OR, 215.1 [95% CI, 64.4 to 597.8], = 6.14 × 10) were enriched in patients with non-clear cell RCCs. PVs in , , and were associated with metastasis ( = .003). Comparative analyses showed an enrichment of PVs in patients from Japan, of and in patients from Canada, the United States and the United Kingdom, and of and in the United States.
, , and are risk genes for RCC in the Canadian population, whereas PVs in / and are associated with risk of metastasis. Globally, clinical guidelines for genetic screening in RCC fail to include more than 70% of patients with rare germline PVs.
非综合征性肾细胞癌(RCC)的遗传易感性仍知之甚少,特别是对于不同的组织学亚型,不同人群的遗传易感性也存在差异。本研究的目的是鉴定加拿大人群中 RCC 的风险基因,研究其临床意义,并评估全球 RCC 患者种系致病性变异(PVs)的差异。
我们对来自加拿大的 960 名 RCC 患者进行了 19 个与 RCC 相关和 27 个癌症易感性基因的靶向测序,并鉴定了与无癌对照相比,在 RCC 中富含罕见种系 PVs 的基因。我们将我们的结果与来自日本、英国和美国的患者报告的结果相结合,以研究不同人群中的 PV 变化。此外,我们评估了纳入具有罕见 PVs 的患者的遗传筛查的转诊标准的性能。
我们在加拿大队列的 56 名患者(5.8%)中发现了 39 个种系 PVs。与无癌对照相比,在透明细胞癌患者中, (比值比 [OR],4.8 [95% CI,2.7 至 7.9], = 3.94×10)和 (OR,4.5 [95% CI,2.0 至 8.7], =.016)中的 PVs 显著富集,而在非透明细胞 RCC 患者中, (OR,215.1 [95% CI,64.4 至 597.8], = 6.14×10)中的 PVs 显著富集。在透明细胞癌患者中, (OR,2.3 [95% CI,1.1 至 4.6], =.023)和 (OR,12.6 [95% CI,4.2 至 37.3], =.001)中的 PVs 与转移相关。比较分析显示,日本患者中 、 、 和 中的 PVs 富集,加拿大、美国和英国患者中 、 和 中的 PVs 富集,美国患者中 、 和 中的 PVs 富集。
在加拿大人群中, 、 、 和 是 RCC 的风险基因,而 / 和 中的 PVs 与转移风险相关。在全球范围内,RCC 遗传筛查的临床指南未能纳入超过 70%的具有罕见种系 PVs 的患者。